Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29778984 | 0.88 | BRD4 (0.47) | MAPK8YTHDC1 | |
| SCHEMBL29136046 | 0.88 | BRD4 (0.47) | MAPK8YTHDC1 | |
| SCHEMBL30656595 | 0.87 | MAPK8 (0.46) | MAPK8IDO1ALDH1A1HIF1A | |
| SCHEMBL29136045 | 0.87 | MAPK8 (0.46) | MAPK8IDO1ALDH1A1HIF1A | |
| SCHEMBL6179524 | 0.81 | MAPK8 (0.56) | MAPK8MAPTMAPK10IDO1LOXL2 | |
| SCHEMBL29779016 | 0.79 | IDO1 (0.54) | MAPK8MAPTMAPK10IDO1ALDH1A1 | |
| SCHEMBL15523614 | 0.78 | MAPT (0.53) | MAPK8MAPTMAPK10IDO1USP2 | |
| SCHEMBL12284564 | 0.77 | KDM4E (0.59) | MAPK8MAPK10ALDH1A1KDM4E | |
| SCHEMBL4710943 | 0.74 | MAPK8 (1.00) | MAPK8MAPK10 | |
| SCHEMBL12284876 | 0.74 | MAPK8 (0.54) | MAPK8MAPK10USP2ALDH1A1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | disclosed |
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | ROCK2, ROCK1, MYLK3 | MAPK8 510/4885MAPT 771/4885MAPK10 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.